Back

Middle-term safety and efficacy after stereotactic arrhythmia radiotherapy: results from the prospective STARNL registry

12 April 2026 (12:30 - 13:15)
Organised by: Logo
Congress Presentation Part of: Radiotherapy in ventricular arrhythmias Radiotherapy EHRA Premium Access EHRA 2026 European Heart Rhythm Association (EHRA)

About the speaker

Photo
Mr Wiert Hoeksema

Amsterdam University Medical Centre (AUMC), Amsterdam (Netherlands (The))

6 More presentations in this session

Presentation thumbnail
Myocardial remodelling phenotypes after cardiac stereotactic body radiotherapy assessed by serial late-gadolinium enhanced cardiac MRI
Doctor P. Bhagirath (Barcelona, ES)
Abstract Slides Video
Presentation thumbnail
Cardiac SABR vs. catheter ablation for VT in high-risk IHD patients: early experience from a UK centre
Mr D. Hunnybun (Sheffield, GB)
Abstract Slides Video
Presentation thumbnail
Patterns of practice and treatment planning for stereotactic arrhythmia radioablation (STAR) for ventricular tachycardia: an ad-hoc analysis of the German cohort within the STOPSTORM.eu consortium
Associate Professor O. Blanck (Kiel, DE)
Abstract Slides Video
Presentation thumbnail
Standardization of stereotactic arrhythmia radioablation (STAR): a systematic meta-review on reporting quality and adherence to EHRA and ICRU recommendations on behalf of the STOPSTORM.eu consortium
Miss Y. Kaya (Maastricht, NL)
Abstract Slides Video
Presentation thumbnail
Stereotactic arrhythmia radiotherapy for refractory ventricular tachycardia: Interim safety and efficacy results from the ongoing prospective STARNL-2 trial
Mr W. Hoeksema (Amsterdam, NL)
Abstract Slides Video

Access the full session

Session thumbnail
Radiotherapy in ventricular arrhythmias

The Event

Event poster

EHRA 2026

12 April 2026 12:30 CET
You may be interested in
thumbnail
Congress Presentation
Selective body radiotherapy
thumbnail
Congress Presentation
Preferred approach in bailout procedures: radiation therapy
thumbnail
Congress Presentation
Stereotactic arrhythmia radiotherapy for refractory ventricular tachycardia: Interim safety and efficacy results from the ongoing prospective STARNL-2 trial

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources